An open-label, phase 2, long-term safety study of inhaled insulin: an up to four-year extension of therapy in subjects with type 1 or type 2 diabetes mellitus participating in extension protocols 217-102, 103, or 104.
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2010
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 10 Nov 2009 Planned number of patients changed from 70 to 173 as reported by ClinicalTrials.gov.
- 19 Dec 2007 Status changed from in progress to discontinued. Clinicaltrials.gov states "Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons."